当前位置: X-MOL 学术Stem Cells Int. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Specific Blood Cells Derived from Pluripotent Stem Cells: An Emerging Field with Great Potential in Clinical Cell Therapy
Stem Cells International ( IF 3.8 ) Pub Date : 2021-08-15 , DOI: 10.1155/2021/9919422
Qian Luo 1, 2, 3, 4 , Honghu Li 1, 2, 3, 4 , Wei Shan 1, 2, 3, 4 , Cong Wei 1, 2, 3, 4 , Yan Long 1, 2, 3, 4 , Shuyang Cai 1, 2, 3, 4 , Xiangjun Zeng 1, 2, 3, 4 , Xue Li 1, 2, 3, 4 , Yulin Xu 1, 2, 3, 4 , Xiaoxiao Xu 1, 2, 3, 4 , Yi Luo 1, 2, 3, 4 , Pengxu Qian 1, 2, 3, 4, 5, 6 , He Huang 1, 2, 3, 4, 5
Affiliation  

Widely known for self-renewal and multilineage differentiation, stem cells can be differentiated into all specialized tissues and cells in the body. In the past few years, a number of researchers have focused on deriving hematopoietic stem cells (HSCs) from pluripotent stem cells (PSCs) as alternative sources for clinic. Existing findings demonstrated that it is feasible to obtain HSCs and certain mature blood lineages from PSCs, except for several issues to be addressed. This short review outlines the technologies used for hematopoietic differentiation in recent years. In addition, the therapeutic value of PSCs as a potential source of various blood cells is also discussed as well as its challenges and directions in future clinical applications.

中文翻译:

源自多能干细胞的特定血细胞:临床细胞治疗中具有巨大潜力的新兴领域

干细胞以自我更新和多向分化而广为人知,可以分化为体内所有特化组织和细胞。在过去几年中,许多研究人员专注于从多能干细胞 (PSC) 中衍生造血干细胞 (HSC) 作为临床的替代来源。现有研究结果表明,除了需要解决的几个问题外,从 PSC 获得 HSC 和某些成熟的血系是可行的。这篇简短的综述概述了近年来用于造血分化的技术。此外,还讨论了 PSC 作为各种血细胞的潜在来源的治疗价值,以及其在未来临床应用中的挑战和方向。
更新日期:2021-09-20
down
wechat
bug